80-lead ecg body surface mapping (Heartscape Technologies Inc)
Structured Review
80 Lead Ecg Body Surface Mapping, supplied by Heartscape Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/lead+surface+ecg/80+lead+body+surface+map++bsm++ecg/pm19766352-35-22-30
Average 90 stars, based on 1 article reviews
Images
Related Articles
other:Article Title: Body surface mapping vs 12-lead electrocardiography to detect ST-elevation myocardial infarction. Article Snippet: A prospective, multicenter trial was conducted in patients with nontraumatic chest pain in 4 hospitals to determine whether an 80-lead body surface map electrocardiogram system (80-lead BSM ECG) improves detection of ST-segment elevation in acute myocardial infarction (STEMI) compared with a standard 12-lead electrocardiogram (ECG) in an emergency department (ED) setting.. A trained ED or cardiology staff member (technician or nurse) recorded a 12-lead ECG and 80-lead BSM ECG from each subject at initial presentation.. Serial biomarkers (total creatine kinase [CK], CK-MB, and/or troponin) were obtained according to individual hospital practice. Article Title: Optimization of the precordial leads of the 12-lead electrocardiogram may improve detection of ST-segment elevation myocardial infarction. Article Snippet: Background: For the assessment of patients with chest pain, the 12-lead electrocardiogram (ECG) is ☆ Conflicts of Int ⁎ Corresponding Royal Victoria Hosp Kingdom.. E-mail address: p 1 Dr Peter Scott re Royal Research Fellow 0022-0736/$ – see fro doi:10.1016/j.jelectroc the initial investigation.. Major management decisions are based on the ECG findings, both for attempted coronary artery revascularization and risk stratification. Article Title: Acute detection of ST-elevation myocardial infarction missed on standard 12-Lead ECG with a novel 80-lead real-time digital body surface map: primary results from the multicenter OCCULT MI trial. Article Snippet: James W. Hoekstra, MD Brian J. O’Neill, MD Yuri B.. Pride, MD Cedric Lefebvre, MD Deborah B. Diercks, MD W. Frank Peacock, MD Gregory J. Fermann, MD C. Michael Gibson, MD Duane Pinto, MD Jim Giglio, MD Abhinav Chandra, MD Charles B. Cairns, MD Marvin A. Konstam, MD Joe Massaro, PhD Mitchell Krucoff, MD From Wake Forest University, Winston-Salem, NC (Hoekstra, Lefebvre); Wayne State University, Detroit, MI (O’Neill); Beth Israel Deaconess Medical Center, Boston, MA (Pride, Gibson, Gibson, Pinto); University of California Davis, Sacramento, CA (Diercks); Cleveland Clinic Foundation, Cleveland, OH (Peacock); University of Cincinnati, Cincinnati, OH (Fermann); New York Presbyterian Hospital, New York, NY (Giglio); Duke University Medical Center, Durham, NC (Chandra, Krucoff); University of North Carolina, Chapel Hill, NC (Cairns); Tufts University Medical Center, Boston, MA (Konstam); and Boston University, Boston, MA (Massaro). |
